JP7603662B2 - 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法 - Google Patents

特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法 Download PDF

Info

Publication number
JP7603662B2
JP7603662B2 JP2022512341A JP2022512341A JP7603662B2 JP 7603662 B2 JP7603662 B2 JP 7603662B2 JP 2022512341 A JP2022512341 A JP 2022512341A JP 2022512341 A JP2022512341 A JP 2022512341A JP 7603662 B2 JP7603662 B2 JP 7603662B2
Authority
JP
Japan
Prior art keywords
composition
hexahydro
dimethoxy
isoquinolin
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022512341A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544711A5 (cg-RX-API-DMAC10.html
JP2022544711A (ja
Inventor
ゴードン ラファエル ローウェン，
シャ ローザ ルオ，
Original Assignee
ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72292706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7603662(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ニューロクライン バイオサイエンシーズ，インコーポレイテッド filed Critical ニューロクライン バイオサイエンシーズ，インコーポレイテッド
Publication of JP2022544711A publication Critical patent/JP2022544711A/ja
Publication of JP2022544711A5 publication Critical patent/JP2022544711A5/ja
Priority to JP2024185429A priority Critical patent/JP2025003553A/ja
Application granted granted Critical
Publication of JP7603662B2 publication Critical patent/JP7603662B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022512341A 2019-08-23 2020-08-21 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法 Active JP7603662B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024185429A JP2025003553A (ja) 2019-08-23 2024-10-21 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962890697P 2019-08-23 2019-08-23
US62/890,697 2019-08-23
US202063028754P 2020-05-22 2020-05-22
US63/028,754 2020-05-22
PCT/US2020/047392 WO2021041208A1 (en) 2019-08-23 2020-08-21 Methods for the administration of certain vmat2 inhibitors to patients with severe renal impairment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024185429A Division JP2025003553A (ja) 2019-08-23 2024-10-21 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法

Publications (3)

Publication Number Publication Date
JP2022544711A JP2022544711A (ja) 2022-10-20
JP2022544711A5 JP2022544711A5 (cg-RX-API-DMAC10.html) 2023-08-15
JP7603662B2 true JP7603662B2 (ja) 2024-12-20

Family

ID=72292706

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022512341A Active JP7603662B2 (ja) 2019-08-23 2020-08-21 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法
JP2024185429A Pending JP2025003553A (ja) 2019-08-23 2024-10-21 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024185429A Pending JP2025003553A (ja) 2019-08-23 2024-10-21 特定のｖｍａｔ２阻害剤を重度腎障害の患者に投与するための方法

Country Status (26)

Country Link
US (1) US10940141B1 (cg-RX-API-DMAC10.html)
EP (2) EP4652986A3 (cg-RX-API-DMAC10.html)
JP (2) JP7603662B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220051239A (cg-RX-API-DMAC10.html)
CN (1) CN114679906A (cg-RX-API-DMAC10.html)
AU (2) AU2020336017B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022002834A2 (cg-RX-API-DMAC10.html)
CA (1) CA3149033A1 (cg-RX-API-DMAC10.html)
DK (1) DK4017494T3 (cg-RX-API-DMAC10.html)
ES (1) ES3040583T3 (cg-RX-API-DMAC10.html)
FI (1) FI4017494T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20251281T1 (cg-RX-API-DMAC10.html)
HU (1) HUE073484T2 (cg-RX-API-DMAC10.html)
IL (1) IL290686B2 (cg-RX-API-DMAC10.html)
JO (1) JOP20220040A1 (cg-RX-API-DMAC10.html)
LT (1) LT4017494T (cg-RX-API-DMAC10.html)
MA (1) MA56930B1 (cg-RX-API-DMAC10.html)
MD (1) MD4017494T2 (cg-RX-API-DMAC10.html)
MX (1) MX2022000559A (cg-RX-API-DMAC10.html)
PH (1) PH12022550385A1 (cg-RX-API-DMAC10.html)
PT (1) PT4017494T (cg-RX-API-DMAC10.html)
RS (1) RS67194B1 (cg-RX-API-DMAC10.html)
SI (1) SI4017494T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202500480T1 (cg-RX-API-DMAC10.html)
TW (1) TWI894161B (cg-RX-API-DMAC10.html)
WO (1) WO2021041208A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230170136A (ko) 2017-01-27 2023-12-18 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US20240197714A1 (en) * 2021-04-15 2024-06-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
JP2024514873A (ja) * 2021-04-15 2024-04-03 ニューロクライン バイオサイエンシーズ，インコーポレイテッド デューテトラベナジンおよびｃｙｐ２ｄ６阻害剤の併用投与のための方法
IL309172A (en) 2021-06-30 2024-02-01 Neurocrine Biosciences Inc Vulbanazine for use in the additional treatment of schizophrenia
CA3221728A1 (en) * 2021-06-30 2023-01-05 Grace S. LIANG Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
CA3245030A1 (en) 2022-03-07 2023-09-14 Neurocrine Biosciences, Inc. VALBENAZINE, A VMAT2 INHIBITOR, AS A FREE BASE OF A TOSYLATE OR DITOSYLATE SALT, INTENDED FOR USE IN THE TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE
WO2025038959A1 (en) 2023-08-17 2025-02-20 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors
TW202521119A (zh) 2023-08-17 2025-06-01 美商紐羅克里生物科學有限公司 用於投與特定vmat2抑制劑之方法
WO2025096823A1 (en) 2023-11-01 2025-05-08 Neurocrine Biosciences, Inc. Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
WO2025188830A1 (en) 2024-03-06 2025-09-12 Neurocrine Biosciences, Inc. Methods for the administration of certain vmat2 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140093A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
WO2018153632A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5777697A (en) 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
JPS57209225A (en) 1981-06-18 1982-12-22 Yamasa Shoyu Co Ltd Antitumor activity intensifier
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5798119A (en) 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
AU1321900A (en) 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
WO2003099011A1 (en) 2002-05-28 2003-12-04 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
CA2499601A1 (en) 2002-09-19 2004-04-01 University Of Utah Research Foundation Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
SG183012A1 (en) 2004-06-04 2012-08-30 Genentech Inc Method for treating multiple sclerosis
ES2318771T3 (es) 2005-08-06 2009-05-01 Cambridge Laboratories (Ireland) Limited 3,11b-cis-dihidrotetrabenazinas para el tratamiento de la esquizofrenia y otras psicosis.
US20100076087A1 (en) 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
GB0721669D0 (en) 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
BRPI0906962B8 (pt) 2008-01-18 2021-05-25 Eisai R&D Man Co Ltd composto de aminodiidrotiazina fundido
US20110053866A1 (en) 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
WO2011019956A2 (en) 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463452A (en) 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
US20100096319A1 (en) 2008-10-17 2010-04-22 General Electric Company Separator assembly
US20120003330A1 (en) 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
IL266159B2 (en) 2012-12-18 2024-07-01 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
EA202091397A1 (ru) 2013-01-31 2020-09-04 Ауспекс Фармацетикалс, Инк. Бензохинолоновые ингибиторы vmat2
WO2015077521A1 (en) 2013-11-22 2015-05-28 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
KR20160111999A (ko) 2014-01-27 2016-09-27 오스펙스 파마슈티칼스, 인코포레이티드 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제
MX2016010213A (es) 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
US9782398B2 (en) 2014-02-07 2017-10-10 Neurocrine Biosciences, Inc. Pharmaceutical compositions comprising an antipsychotic drug and a VMAT2 inhibitor and uses thereof
FI3936130T3 (fi) 2014-05-06 2024-04-23 Neurocrine Biosciences Inc Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
KR102586138B1 (ko) 2015-02-06 2023-10-05 뉴로크린 바이오사이언시즈 인코퍼레이티드 [9,10-디메톡시-3-(2-메틸프로필)-1H,2H,3H,4H,6H,7H,11bH-피리도-[2,1-a]이소퀴놀린-2-일]메탄올 및 그와 관련된 화합물, 조성물 및 방법
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
US20190015396A1 (en) 2015-06-23 2019-01-17 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
DK3368534T3 (da) 2015-10-30 2021-02-15 Neurocrine Biosciences Inc Valbenazin-ditosylat og polymorfer deraf
DK3394057T3 (da) 2015-12-23 2022-04-11 Neurocrine Biosciences Inc Syntetisk fremgangsmåde til fremstilling af (S)-(2R,3R,11BR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11B-hexahydro-1H-pyrido[2,1,-A]isoquinolin-2-yl 2-amino-3-methylbutanoat-di(4-methylbenzensulfonat)
TW202515564A (zh) 2016-12-02 2025-04-16 美商紐羅克里生物科學有限公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
WO2018164996A1 (en) * 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
JP2020512986A (ja) 2017-04-01 2020-04-30 アデプティオ ファーマシューティカルズ リミテッド 運動障害の治療に使用するための（＋）−α−ジヒドロテトラベナジン
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
KR20200010320A (ko) 2017-05-16 2020-01-30 보우 리버 엘엘씨 치료 방법
CA3076000A1 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US20200230127A1 (en) 2017-10-10 2020-07-23 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
JOP20200298A1 (ar) 2018-06-14 2020-11-22 Neurocrine Biosciences Inc مركبات مثبطة لـ vmat2 وتركيبات وطرق تتعلق بها
SG11202100303QA (en) 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10689380B1 (en) 2019-07-30 2020-06-23 Farmhispania S.A. Crystalline forms of valbenazine ditosylate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140093A1 (en) 2017-01-27 2018-08-02 Obrien Christopher F Methods for the administration of certain vmat2 inhibitors
WO2018153632A1 (en) 2017-02-27 2018-08-30 Sandoz Ag Crystalline forms of valbenazine salts

Also Published As

Publication number Publication date
LT4017494T (lt) 2025-10-27
MD4017494T2 (ro) 2026-03-31
IL290686A (en) 2022-04-01
JP2022544711A (ja) 2022-10-20
MA56930B1 (fr) 2025-10-31
PT4017494T (pt) 2025-09-16
EP4017494B1 (en) 2025-08-20
HRP20251281T1 (hr) 2025-12-05
AU2020336017A1 (en) 2022-04-07
CN114679906A (zh) 2022-06-28
JOP20220040A1 (ar) 2023-01-30
DK4017494T3 (da) 2025-09-15
TW202114675A (zh) 2021-04-16
IL290686B1 (en) 2025-03-01
AU2020336017B2 (en) 2025-09-18
AU2025279628A1 (en) 2026-01-15
MX2022000559A (es) 2022-02-10
SMT202500480T1 (it) 2026-01-12
EP4652986A3 (en) 2026-01-07
US10940141B1 (en) 2021-03-09
TWI894161B (zh) 2025-08-21
SI4017494T1 (sl) 2025-10-30
RS67194B1 (sr) 2025-10-31
EP4017494A1 (en) 2022-06-29
FI4017494T3 (fi) 2025-10-08
ES3040583T3 (en) 2025-11-03
EP4652986A2 (en) 2025-11-26
JP2025003553A (ja) 2025-01-09
PH12022550385A1 (en) 2023-12-04
BR112022002834A2 (pt) 2022-06-28
WO2021041208A1 (en) 2021-03-04
US20210052558A1 (en) 2021-02-25
HUE073484T2 (hu) 2026-01-28
CA3149033A1 (en) 2021-03-04
IL290686B2 (en) 2025-07-01
KR20220051239A (ko) 2022-04-26

Similar Documents

Publication Publication Date Title
US10940141B1 (en) Methods for the administration of certain VMAT2 inhibitors
TWI850377B (zh) 特定vmat2抑制劑之投與方法
US11026931B2 (en) Methods for the administration of certain VMAT2 inhibitors
TW201829365A (zh) 苯甲酸鈉之同素異形體形式及其用途
TW202345830A (zh) 特定vmat2抑制劑的投予方法
HK40068979B (en) The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment
HK40068979A (en) The vmat2 inhibitor valbenazine for use in a method of treating a neurological or psychiatric disorder in patients with severe renal impairment
WO2025038959A1 (en) Methods for the administration of certain vmat2 inhibitors
WO2025038938A1 (en) Valbenazine for use in the treatment of huntington's chorea
WO2025096823A1 (en) Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241021

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241210

R150 Certificate of patent or registration of utility model

Ref document number: 7603662

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350